Screener / SEC EDGAR /CIK 0001420800 /10-K filed Feb 26, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Devices

Enovis CORP ENOV

Compare with peers Embed
New in the 10-K 4 paragraphs with nothing like them in the 10-K filed Feb 26, 2025 New in the 10-Q 9 paragraphs not in the 10-Q filed Aug 6, 2026 10-Q against the 10-K 2 risk factor paragraphs and sentences added or reworded

New risk paragraphs, branching off last year

Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 26, 2025. A box jumps to the paragraph as filed, below.

4 new

Paragraphs with nothing like them in last year's 10-K

Quoted exactly

4 paragraphs in Risk Factors of the 10-K filed Feb 26, 2026 with nothing like them in the 10-K filed Feb 26, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.

penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations.

Read in the 10-K

Our use of artificial intelligence and machine‑learning technologies may expose us to operational, regulatory, and reputational risks.

We use, and may increasingly use, artificial intelligence (“AI”) and machine‑learning technologies to support aspects of our operations, product development, and business processes. AI technologies are rapidly evolving and may produce unintended, inaccurate, or inconsistent results. If these technologies do not perform as expected, are misused, or are not appropriately governed, our operations, compliance efforts, and reputation could be adversely affected.

Read in the 10-K

In addition, changes in political conditions in China and changes in the state of China-U.S. relations, including any tensions relating to potential military conflict between China and Taiwan, are difficult to predict and could adversely affect our business. Furthermore, if other countries, including the United States, become further involved in these or other conflicts, we could face significant adverse effects to our business and financial condition.

Read in the 10-K

Paragraphs in the 10-Q filed Nov 5, 2026 that were not in the one before

New in the latest 10-Q

9 paragraphs in the 10-Q filed Nov 5, 2026 with nothing like them in the 10-Q filed Aug 6, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.

Financial statements and notes

During the three months ended October 2, 2026, due to a decrease in the share price of our common stock and market capitalization, the Company identified a possible impairment indicator as of October 2, 2026 and determined it was appropriate to perform interim quantitative assessments of Goodwill for the P&R and Recon reporting units. Based on these assessments, no impairment was identified.

Read in the 10-Q

On August 31, 2026, the Company entered into a binding offer to acquire eCential Robotics SAS (“eCential”), a leading developer of enabling technologies and surgical robotics, for an enterprise value, net of acquired cash, of approximately € 155.0 million, subject to certain adjustments, which corresponds to approximately € 176.0 million in up-front cash consideration to be paid to eCential’s shareholders at closing, and up to an additional € 35.0 million to be paid in cash upon the achievement of certain milestones, as defined in the terms of the definitive securities purchase agreement, which was executed on September 28, 2026, following the completion of the required works council consultation process (the “eCential Acquisition”). The closing of the eCential Acquisition is subject to the receipt of applicable regulatory approvals and other customary closing conditions and is expected to be completed in the fourth quarter of 2026.

Read in the 10-Q

On November 2, 2026, the Board of Directors terminated the previous share repurchase program and approved a new share repurchase program authorizing the repurchase of up to $ 200 million in shares of the Company's Common Stock. The manner, timing and amount of any repurchases under the program will be determined by the Company’s management based on its evaluation of market conditions, stock price, liquidity, and other factors, and will be executed in accordance with applicable securities laws and regulations. Repurchases under the program may be made from time to time through open market purchases, privately negotiated transactions, or other means, including pursuant to a Rule 10b5-1 trading plan. The repurchase program does not obligate the Company to acquire a specific dollar amount or number of shares, has no expiration date and may be modified, suspended or discontinued at any time.

Read in the 10-Q

In July 2026, the Company paid $ 3.2 million to reduce a portion of its cross-currency swap liability in conjunction with amending and extending the agreements. This cash outflow is reflected within investing activities in the Company’s Condensed Consolidated Statement of Cash Flows. Of all its cross-currency swap agreements, only one agreement with a Swiss Franc notional amount of CHF 45.3 million matures in the next twelve months. The remaining agreements mature in the years 2028 to 2030.

Read in the 10-Q

The Company is involved in various pending legal, regulatory, and other proceedings arising out of the ordinary course of the Company’s business. One such matter relates to a Civil Investigative Demand (“CID”) from the United States Attorney’s Office for the Middle District of Tennessee that sought documents and information from the Company in connection with a civil investigation of a former independent distributor of the Company’s products concerning potential violations of the False Claims Act. The Company has cooperated with the government’s investigation and responded to the CID. Subsequently, the Company received two additional CIDs related to the matter, the last of which identified additional parties as a potential focus of the investigation, including the former independent distributor, its principal, a hospital, certain surgeons and the Company. The Company has continued to cooperate with the investigation and has responded to the additional CIDs. We cannot at this time reasonably predict the ultimate scope or outcome of the matter.

Read in the 10-Q
Show the other 4

On August 31, 2026, the Company entered into a binding offer to acquire eCential Robotics SAS (“eCential”), a leading developer of enabling technologies and surgical robotics, for an enterprise value, net of acquired cash, of approximately €155.0 million, subject to certain adjustments, which corresponds to approximately €176.0 million in up-front cash consideration to be paid to eCential’s shareholders at closing, and up to an additional €35.0 million to be paid in cash upon the achievement of certain milestones, as defined in the terms of the definitive securities purchase agreement, which was executed on September 28, 2026, following the completion of the required works council consultation process. The closing of the eCential Acquisition is subject to the receipt of applicable regulatory approvals and other customary closing conditions and is expected to be completed in the fourth quarter of 2026.

Read in the 10-Q

Operating loss decreased primarily due to the decrease in Goodwill impairment charges, and the aforementioned gross profit increases. Adjusted EBITDA and Adjusted EBITDA margin decreased due to the aforementioned gross margin decrease.

Read in the 10-Q

On November 2, 2026, our Board of Directors terminated the 2018 Share Repurchase Program and approved a new share repurchase program authorizing the repurchase of up to $200 million in shares of our common stock (the “2026 Share Repurchase Program”). The manner, timing and amount of any repurchases under the 2026 Share Repurchase Program will be determined by our management based on its evaluation of market conditions, stock price, liquidity, and other factors, and will be executed in accordance with applicable securities laws and regulations. Repurchases under the program may be made from time to time through open market purchases, privately negotiated transactions, or other means, including pursuant to a Rule 10b5-1 trading plan. The repurchase program does not obligate us to acquire a specific dollar amount or number of shares, has no expiration date and may be modified, suspended or discontinued at any time.

Read in the 10-Q

We evaluate the recoverability of Goodwill at the reporting unit level annually or more frequently if an event occurs or circumstances change in the interim that would more likely than not reduce the fair value of the asset below its carrying amount. Our last quantitative impairment test performed on the first day of the fourth quarter of 2025 resulted in impairment. Due to the decrease in the share price of our common stock, we performed a quantitative goodwill impairment test as of the last day of the third quarter. Such test indicated that no goodwill impairment should be recorded during the quarter. The sum of the fair value of our two reporting units as calculated by management in this quantitative impairment test implies a premium of approximately 46% above our current market capitalization. As of October 2, 2026, the Goodwill of the Prevention & Recovery and Reconstructive reporting units was $390.3 million and $311.8 million, respectively. If there are further declines in our market capitalization or actual results of the business differ from our estimates and projections, there is an increased risk of potential impairment, which could materially affect our financial statements.

Read in the 10-Q

The 10-Q's risk factors against the 10-K

Item 1A of the 10-Q filed Nov 5, 2026 against Item 1A of the 10-K filed Feb 26, 2026. A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed. Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed, Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal (cut words struck through, new words highlighted). Text on the page, not a score; each links to the filing at sec.gov.

Reworded10-Q Nov 5, 2026 vs 10-K Feb 26, 2026
If any of the following risks were to contained in those reports actually occur, our business, results of operation, financial condition, results of operations and liquidity could be materially adversely affected, harmed, the value of our common stock securities could decline decline, and investors you could lose all or part of the value of their investment in Enovis shares. your investment.

Read it in the 10-Q at sec.govThe 10-K sentence

Phrases used for the first time

Two-word phrases in Risk Factors of the 10-K filed Feb 26, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 26, 2025

device regulations ×5armed conflicts ×4middle east ×4recon reporting ×3quarter ended ×2publicly quoted ×2quoted share ×2share price ×2capitalization relative ×2carrying value ×2machine learning ×2learning technologies ×2esab corporation ×2armed conflict ×2
Where each one is used
  • device regulations: In the EU, our notified body issues the certificates that allow CE marking for the sale of our products. To continue to place products on the market in the EU and United Kingdom after expiry of our existing notified body certificate(s), we will need to apply for their certification under the MDR and UK Medical...
  • armed conflicts: Our business, financial condition and results of operations could be adversely affected by disruptions in the global economy caused by geopolitical uncertainty, political instability, and conflicts, such as the armed conflicts between Russia and Ukraine and in the Middle East.
  • middle east: Our business, financial condition and results of operations could be adversely affected by disruptions in the global economy caused by geopolitical uncertainty, political instability, and conflicts, such as the armed conflicts between Russia and Ukraine and in the Middle East.
  • recon reporting: Our total assets reflect substantial intangible assets, primarily Goodwill. The Goodwill results from our acquisitions, representing the excess of cost over the fair value of the net assets we have acquired. We assess annually, or more frequently if an event occurs or circumstances change in the interim that would...
  • quarter ended: Our total assets reflect substantial intangible assets, primarily Goodwill. The Goodwill results from our acquisitions, representing the excess of cost over the fair value of the net assets we have acquired. We assess annually, or more frequently if an event occurs or circumstances change in the interim that would...
  • publicly quoted: Our total assets reflect substantial intangible assets, primarily Goodwill. The Goodwill results from our acquisitions, representing the excess of cost over the fair value of the net assets we have acquired. We assess annually, or more frequently if an event occurs or circumstances change in the interim that would...
  • quoted share: Our total assets reflect substantial intangible assets, primarily Goodwill. The Goodwill results from our acquisitions, representing the excess of cost over the fair value of the net assets we have acquired. We assess annually, or more frequently if an event occurs or circumstances change in the interim that would...
  • share price: Our total assets reflect substantial intangible assets, primarily Goodwill. The Goodwill results from our acquisitions, representing the excess of cost over the fair value of the net assets we have acquired. We assess annually, or more frequently if an event occurs or circumstances change in the interim that would...

The 10-K at sec.gov

Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.

What was taken out

7 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.

Across all companies
For example, as a result of the COVID-19 pandemic, we experienced adverse impacts on sales, as well as material delays and periodic cancellations of elective medical procedures, orthopedic clinics and physical therapy centers operating at reduced levels, and periodic cancellation of sports programs impacting our business. The effect of the COVID-19 pandemic on the global economy resulted in a number of additional challenges for our business, including cost inflation, supply chain challenges such as logistics delays, and healthcare provider staffing shortages, all of which are attributable...
In the 10-K filed Feb 26, 2025
The global economy has been negatively impacted by the military conflict between Russia and Ukraine. Furthermore, governments in the United States, United Kingdom and European Union have each imposed export controls on certain products and financial and economic sanctions on certain industry sectors and parties in Russia, and Russia has imposed counter-
In the 10-K filed Feb 26, 2025
debarment from government contracts, curtailment of operations in certain jurisdictions, competitive or reputational harm, litigation or regulatory action and other consequences that might adversely affect our results of operations, financial condition or strategic objectives.
In the 10-K filed Feb 26, 2025
marking or new products or modified products. If any of these actions were to occur, it would harm our reputation and cause our product sales and profitability to suffer and may prevent us from generating revenue.
In the 10-K filed Feb 26, 2025

Sources

Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.

Also

10-K change: what was reworded or cut, section by section.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ENOV/export.csv") into a cell.

Next:10-K change
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.